4
MARKET OVERVIEW
Outlines emerging trends, technology impact, and regulatory signals affecting growth trajectory and stakeholder decisions.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Maps the market evolution with focus on trend catalysts, risk factors, and growth opportunities across segments.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN US HEALTHCARE INDUSTRY
5.2.4
TRENDS IN US DRUG DELIVERY INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY END-USE INDUSTRY, (2022–2025)
5.6.2
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, (2022–2025)
5.7.1
IMPORT SCENARIO (HS CODE 901890)
5.7.2
EXPORT SCENARIO (HS CODE 901890)
5.8
KEY CONFERENCES AND EVENTS, 2026–2027
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10
INVESTMENT AND FUNDING SCENARIO
5.11
SUCCESS STORIES AND REAL-WORLD APPLICATIONS
5.12
IMPACT OF 2025 US TARIFF – US INJECTABLE DRUG DELIVERY MARKET
5.12.3
PRICE IMPACT ANALYSIS
5.12.5
IMPACT ON END-USE INDUSTRIES
5.12.5.1
HOSPITALS & CLINICS
5.12.5.2
HOME CARE SETTINGS
5.12.5.3
LONG-TERM CARE SETTINGS
NOTE: OTHER END USERS INCLUDE COSMETIC CLINICS, DIAGNOSTIC LABORATORIES, CLINICAL RESEARCH, ACADEMIC & RESEARCH INSTITUTIONS, AND HEALTHCARE PROVIDERS.
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.1.1
AUTOINJECTORS AND SMART INJECTION DEVICES
6.1.2
NEEDLE-FREE INJECTION SYSTEMS AND MICRONEEDLE PATCHES
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.2
BIODEGRADABLE POLYMERS
6.3
ADJACENT TECHNOLOGIES
6.3.1
ARTIFICIAL INTELLIGENCE AND DIGITAL THERAPEUTICS
6.3.2
ALTERNATIVE ROUTES OF ADMINISTRATION
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.7
IMPACT OF AI/GEN AI ON US INJECTABLE DRUG DELIVERY MARKET
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
BEST PRACTICES IN US INJECTABLE DRUG DELIVERY MARKET
6.7.3
CASE STUDIES OF AI IMPLEMENTATION IN US INJECTABLE DRUG DELIVERY MARKET
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN US INJECTABLE DRUG DELIVERY MARKET
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
SUSTAINABILITY INITIATIVES
7.2.1
ENERGY-EFFICIENT SYSTEM DESIGN AND USE OF RECYCLABLE MATERIALS IN INJETCABLE DRUG DELIVERY PRODUCTS
7.3
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.4
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
US INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
COMPARATIVE ASSESSMENT OF KEY INJECTABLE DRUG DELIVERY PRODUCTS, THEIR MARKET POTENTIAL, AND DEMAND PATTERNS BY VARIOUS MANUFACTURERS
Market Size, Volume & Forecast – USD Million
9.2
US VOLUME ANALYSIS OF INJECTABLE DRUG DELIVERY PRODUCTS, 2024–2031 (THOUSAND UNITS)
9.3.1
CONVENTIONAL INJECTION DEVICES
9.3.1.1.1
GLASS INJECTABLE DEVICES
9.3.1.1.2
PLASTIC INJECTABLE DEVICES
9.3.1.2.1
FILLABLE SYRINGES
9.3.1.2.2
PREFILLED SYRINGES
9.3.1.3.1
REUSABLE INJECTION DEVICES
9.3.1.3.2
DISPOSABLE INJECTION DEVICES
9.3.2
SELF-INJECTION DEVICES
9.3.2.1
NEEDLE-FREE INJECTORS
9.3.2.4
WEARABLE INJECTORS
9.3.2.5
OTHER SELF-INJECTION DEVICES
NOTE: OTHER INJECTABLE DEVICES INCLUDE BLUNT NEEDLES, MICRONEEDLES, AND NANONEEDLE INJECTIONS.
9.4.1
CONVENTIONAL DRUG DELIVERY FORMULATIONS
9.4.1.2
RECONSTITUTED/LYOPHILIZED FORMULATIONS
9.4.2
NOVEL DRUG DELIVERY FORMULATIONS
9.4.2.1
COLLOIDAL DISPERSIONS
9.4.2.1.3
POLYMERIC/MIXED MICELLES
9.4.3
LONG-ACTING INJECTABLE FORMULATIONS
10
US INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
FORMULATION PACKAGING-WISE DEMAND POTENTIAL AND GROWTH PATHWAYS SHAPING INJETCABLE DRUG DELIVERY ADOPTION IN DIVERSE INDUSTRIES
11
US INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
THERAPEUTIC APPLICATION-WISE DEMAND POTENTIAL AND GROWTH PATHWAYS SHAPING VETERINARY IMAGING ADOPTION IN DIVERSE INDUSTRIES
11.2.1
RHEUMATOID ARTHRITIS
11.2.2
MULTIPLE SCLEROSIS
11.2.5
OTHER AUTOIMMUNE DISEASES
11.3.2
REPRODUCTIVE HEALTH DISEASES
11.3.3
ANTITHROMBOTIC/THROMBOLYTIC THERAPY
11.3.5
GROWTH HORMONE DEFICIENCY
11.8
OTHER THERAPEUTIC APPLICATIONS
11.8.3
AESTHETIC TREATMENTS
NOTE: OTHER AUTOIMMUNE DISEASES INCLUDE HEPATITIS, ADDISON’S DISEASE, MYASTHENIA GRAVIS, PERNICIOUS ANEMIA, HASHIMOTO'S THYROIDITIS, CARDIOMYOPATHY, ANTIPHOSPHOLIPID SYNDROME, GUILLAIN-BARRÉ SYNDROME, SJÖGREN’S SYNDROME, AND ALOPECIA.
NOTE: OTHER THERAPEUTIC APPLICATIONS INCLUDE ALLERGIES, AESTHETIC TREATMENT, HEPATITIS C, AND HEMOPHILIA.
12
US INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
USAGE PATTERN DEMAND PATTERNS AND GROWTH DRIVERS IMPACTING INJECTABLE DRUG DELIVERY ADOPTION
12.4
OTHER USAGE PATTERNS
NOTE: OTHER USAGE PATTERNS INCLUDE BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES.
13
US INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
SITE OF ADMINISTRATION-WISE DEMAND POTENTIAL AND GROWTH PATHWAYS SHAPING INJECTABLE DRUG DELIVERY ADOPTION IN DIVERSE INDUSTRIES
13.2
DERMAL-BASED ADMINISTRATION
13.3
CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION
13.4
ORGAN-BASED ADMINISTRATION
13.5
CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION
14
US INJECTABLE DRUG DELIVERY MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
SECTOR-SPECIFIC ADOPTION DRIVERS, DEMAND DYNAMICS, AND MARKET POTENTIAL ACROSS EACH END-USE INDUSTRY
14.4
LONG-TERM CARE SETTINGS
NOTE: OTHER END USERS INCLUDE COSMETIC CLINICS, DIAGNOSTIC LABORATORIES, CLINICAL RESEARCH, ACADEMIC & RESEARCH INSTITUTIONS, AND HEALTHCARE PROVIDERS.
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
15.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
15.4
MARKET SHARE ANALYSIS
15.5
BRAND/PRODUCT COMPARISON
15.5.1
BD (BD PHYSIOJECT)
15.5.2
WEST PHARMACEUTICAL SERVICES, INC. (SMARTDOSE SYSTEM)
15.5.3
CARDINAL HEALTH (MONOJECT)
15.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
15.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
15.6.5.1
COMPANY FOOTPRINT
15.6.5.2
PRODUCT FOOTPRINT
15.6.5.3
FORMULATION PACKAGING FOOTPRINT
15.6.5.4
THERAPEUTIC APPLICATION FOOTPRINT
15.6.5.5
USAGE PATTERN FOOTPRINT
15.6.5.6
SITE OF ADMINISTRATION FOOTPRINT
15.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
15.7.1
PROGRESSIVE COMPANIES
15.7.2
RESPONSIVE COMPANIES
15.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
15.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
15.7.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
15.8
COMPANY VALUATION AND FINANCIAL METRICS
15.9
COMPETITIVE SCENARIO
15.9.4
OTHER DEVELOPMENTS
IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE US INJECTABLE DRUG DELIVERY MARKET LANDSCAPE
16.1
INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
16.1.2
WEST PHARMACEUTICAL SERVICES, INC.
16.1.7
TERUMO CORPORATION
16.2
INJETCABLE DRUG DELIVERY FORMULATION MANUFACTURERS
16.2.4
ELI LILLY AND COMPANY
16.2.7
F. HOFFMANN-LA ROCHE LTD
16.2.8
BRISTOL-MYERS SQUIBB COMPANY
17.1.1.1
KEY DATA FROM SECONDARY SOURCES
17.1.2.1
KEY DATA FROM PRIMARY SOURCES
17.1.2.2
KEY PRIMARY PARTICIPANTS
17.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
17.1.2.4
KEY INDUSTRY INSIGHTS
17.2
MARKET SIZE ESTIMATION
17.2.1
BOTTOM-UP APPROACH
17.2.3
BASE NUMBER CALCULATION
17.3
MARKET FORECAST APPROACH
17.6
RESEARCH ASSUMPTIONS
17.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3
CUSTOMIZATION OPTIONS
18.3.2
COMPANY INFORMATION
18.3.3
GEOGRAPHIC ANALYSIS
18.3.4
REGIONAL/COUNTRY LEVEL MARKET SHARE ANALYSIS
18.3.5
COUNTRY LEVEL VOLUME ANALYSIS
18.3.6
BY TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
18.3.7
ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS
*CONTENTS IN THE TOC/ MARKET SEGMENTS ARE TENTATIVE AND MIGHT CHANGE AS THE RESEARCH PROCEEDS.
*LIST OF COMPANIES IS NOT EXHAUSTIVE AND MIGHT CHANGE DURING COURSE OF STUDY
Growth opportunities and latent adjacency in US Injectable Drug Delivery Market